H

Hospital Nacional Edgardo Rebagliati Martins | Medical Oncology

Research site

(Unclaimed)

Location

Av. Edgardo Rebagliati 490- Jesus Maria, Lima, Lima, Peru

Site insights

Top conditions

Top treatments

BIIB059

Gemcitabine

Bevacizumab

Litifilimab

Estrogen

Giredestrant

Docetaxel

Cisplatin

Bosutinib

Atezolizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 18 total trials

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling

Early Breast Cancer

Drug: Endocrine Therapy of Physician's Choice

Drug: Abemaciclib

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST)

This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immuno...

Active, not recruiting

Non-Small Cell Lung Cancer

Drug: Docetaxel

Drug: Entrectinib

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus (TOPAZ-1)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). T...

Enrolling

Lupus Erythematosus, Systemic

Drug: Placebo

Drug: Litifilimab

Locations recently updated

An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus (EMERALD)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). T...

Invitation-only

Systemic Lupus Erythematosus (SLE)

Drug: Litifilimab-matching placebo

Drug: Litifilimab